Duplicate Therapy
Customize your policy alerts
Sign up for meridian Policy MDN.CP.PMN.351 alerts
Get alerted when Policy MDN.CP.PMN.351 changes without checking for updates manually.
Monitor payer policy activity
Defines Meridian's restrictions and prior authorization requirements to prevent members from receiving excessive or duplicated medications within the same or similar drug classes; applies to Meridian IL Medicaid pharmacy claims and providers seeking overrides or prior authorization.
No material clinical or coverage changes in this revision.
Coverage Criteria
General approval criteria
Pharmacist review and approval criteria
Approval duration: 12 months. Examples where approval may be appropriate include therapy changes, dose titration with multiple strengths, therapies supported by medical literature, concurrent antipsychotic use for stable patients, concurrent opioid use for cancer patients, multiple antidepressants for multiple indications, and benzodiazepine use for seizure maintenance or rescue.
Drug-class limits
Drug class restrictions (enforced limits)
Exceptions for seizure maintenance or rescue use may be approved
Refer to MDN.CP.PMN.97 Opioid Analgesic Criteria
Appendix B: Therapeutic Alternatives — Not applicable.
Requests that exceed the drug-class restrictions identified in the table must include documentation establishing medical necessity. If medical necessity is not established, the request should be denied per the class-specific limits. Pharmacists review prior authorization requests that exceed these restrictions and may approve only when the documentation demonstrates that the request is medically necessary and within the standard of care.
Coding and Administrative Details
| No codes listed |
Provider Actions and Prior Authorization
Prior authorization required for requests exceeding class limits
Prior authorization is required for any request that exceeds the duplicate therapy restrictions specified by drug class. Overrides are not possible at point-of-sale; providers must submit these requests for pharmacist review and approval.
Pharmacist review and examples of appropriate approval
Pharmacists will review PA requests that exceed the drug-class limits and may approve when medically necessary; examples of appropriate approvals include therapy changes, dose titration, multiple indications, cancer pain, seizure maintenance or rescue benzodiazepines, and concurrent antipsychotic use for stable patients.
- Pharmacist may approve if medically necessary and within standard of care
- Examples: changing therapy, multiple strengths for titration, multiple indications, cancer pain, seizure maintenance/rescue benzodiazepines
Required documentation to support PA requests
Provider must submit clinical documentation supporting medical necessity when requesting a PA for duplicate therapy (examples: office chart notes, lab results, or other clinical information demonstrating the request is standard of care).
- Office chart notes
- Laboratory results
- Other clinical information demonstrating standard of care
Denial trigger when medical necessity not established
Deny the request if medical necessity is not established and the request exceeds the drug-class restrictions identified in the policy table.
- Requests exceeding class-specific limits (e.g., ACEI/ARB 1 drug/month; opioids 2 fills/month) should be denied absent documentation of medical necessity
Background
Duplicate therapy edits are safety and appropriateness pharmacy edits intended to prevent members from receiving excessive medication regimens within the same or similar drug classes. Pharmacists shall review prior authorization requests that exceed the drug-class restrictions and may approve when the request is supported as medically necessary and consistent with standard of care (examples include therapy changes, dose titration with multiple strengths, concurrent antipsychotic therapy in a stable patient, concurrent opioid use for cancer, multiple antidepressants for different indications, and benzodiazepine use for seizure maintenance or rescue).
Definitions
Quantity and Duplicate Therapy Limits
Revision History
Policy MDN.CP.PMN.351 (Duplicate Therapy) became effective.
Policy last reviewed on 2024-01-31; approval duration and drug-class restrictions documented.
Next review scheduled on 2024-01-31.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.